Lumida
/NPCE
⌘K
Neuropace Inc

Neuropace Inc

NPCE
$14.04USD+1.23%+0.17 today

MARKET CAP

481.9M

P/E (TTM)

FWD P/E

DAY RANGE

$14 – $14

52W RANGE

$9
$20

AI Summary

Stalk
StalkMedium

NPCE remains in a Stage 2 advancing uptrend supported by rising EMAs, but the active Blow-Off Top pattern signals a climax of buying pressure and waning momentum. Short-term price is pulling back into the rising 9/21 EMA support zone on early RSI rollover, making immediate entry unfavorable. We will wait for a cleaner pullback into these dynamic support levels before engaging bullishly.

  • Q2 2026 revenue grew 17% YoY to $22.8M, driven by 21.3% RNS system sales growth
  • Raised full-year revenue guidance to $99.5–101.5M, signaling management confidence
  • Q2 2026 net loss was $6.2M, reflecting persistent cash burn
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$45.2M$45.5M$65.4M$79.9M$100.0M
YoY %+0.7%+43.7%+22.1%+25.1%
P / Sales3.7x0.8x3.9x4.1x5.1x
EV / Sales4.6x2.4x4.9x5.0x5.7x
Gross Profit, Adj.$33.4M$32.5M$48.1M$59.1M$77.2M
YoY %-2.8%+48.1%+22.8%+30.7%
Margin %74.0%71.4%73.6%73.9%77.2%
EV / Gross Profit6.2x3.3x6.7x6.8x7.4x
EBITDA, Adj.$-23.4M$-37.8M$-27.0M$-21.5M$-16.1M
YoY %-61.3%+28.6%+20.5%+25.0%
Margin %-51.9%-83.1%-41.3%-26.9%-16.1%
EV / EBITDA-8.9x-2.9x-11.9x-18.6x-35.4x
EBIT$-23.7M$-40.8M$-27.2M$-21.7M$-16.3M
YoY %-71.9%+33.4%+20.3%+24.6%
Margin %-52.5%-89.6%-41.5%-27.1%-16.3%
EV / EBIT-8.8x-2.7x-11.8x-18.4x-34.9x
Net Income$-36.1M$-47.1M$-33.0M$-27.1M$-21.5M
YoY %-30.5%+30.0%+17.6%+20.9%
Net Margin-79.9%-103.4%-50.4%-34.0%-21.5%
EPS (GAAP)-$2.17-$1.91-$1.27-$0.93-$0.66
YoY %+12.0%+33.5%+26.8%+29.0%